Optinose Inc. (NASDAQ: OPTN) stock falls by 4.03% at last close whereas the OPTN stock price gains by 5.88% in the pre-market trading. Optinose is a specialty pharmacy firm based in the United States that caters to the needs of patients treated by ENT and allergy specialists.
- OPTN reported on April 28, 2021 that they would release financial statements and business announcements for the first quarter of 2021 before the market opens on Wednesday, May 5, 2021.
- OPTN has stated that on Tuesday, May 18, 2021, at 5:25 p.m. Eastern Time, Chief Executive Officer Peter Miller will deliver an outline and industry update at the RBC Capital Markets Global Healthcare Conference.
The findings of a recent nationwide study on persistent nasal congestion, its effect on everyday lives, and perception of nasal polyps as a potential cause were released by OPTN on April 27, 2021. Nasal polyps are noncancerous growths that develop in the nasal passages as a result of prolonged inflammation high and deep in the passages, causing symptoms such as cough, runny nose, and frequent sinus infections.
Chronic nasal congestion is a prevalent issue for U.S. adults, according to a Harris on Demand study conducted in collaboration with Optinose. About one-fourth of those who experience nasal congestion experience it almost every day, with the rest (85 percent) indicating that congestion adversely affects their everyday activities. Although most patients with chronic nasal congestion are aware that allergies could be to blame, more than half are unaware that nasal polyps could be the source of their symptoms. Nasal polyps are a frequent cause of nasal symptoms that last longer than 12 weeks.
Given their confusion about the symptoms and what could be causing them, only about half of people with chronic nasal congestion seek treatment from a doctor (allergist or ENT specialist) to investigate the root of their issue.